Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452953 | PMC |
| http://dx.doi.org/10.18502/ijhoscr.v17i2.12641 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acute Reversible Atypical Takotsubo Cardiomyopathy Following Trastuzumab and 5-Fluorouracil in a Young Patient.
Cureus
October 2024
Forth Department of Medicine, School of Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, GRC.
Combined therapeutic regimens, including molecular targeted agents, are considered standard treatment for advanced gastric and gastroesophageal junction cancer. We present an extremely rare case of acute reversible cardiac dysfunction in a 20-year-old patient after administration of trastuzumab plus 5-fluorouracil for the treatment of metastatic gastroesophageal junction cancer. During the first day of chemotherapy, the patient complained of retrosternal pain radiating to the scapular regions bilaterally.
View Article and Find Full Text PDFArtificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images.
Circ Cardiovasc Qual Outcomes
September 2024
Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT; Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT; Section of Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, CT; Section of Health Informatics, Department of Biostatistics, Yale School of Public Health, New Haven, CT.
Article Synopsis
- Researchers evaluated the potential of artificial intelligence (AI) applied to electrocardiograms (ECG) to predict cardiac dysfunction related to cancer treatments, aiming to develop a more scalable risk stratification method.
- In a study involving 1,550 patients treated with anthracyclines and/or trastuzumab, the AI model classified patients into low, intermediate, and high-risk groups based on their baseline ECG images.
- The findings revealed that patients in the high-risk group had significantly higher incidents of cardiac dysfunction within a year post-treatment, highlighting the effectiveness of AI-ECG in identifying those at greater risk for complications.
Chemotherapy-related cardiotoxicity and its symptoms in patients with breast cancer: a scoping review.
Syst Rev
June 2024
College of Nursing and Mo-Im Kim Nursing Research Institute, Yonsei University, 50-1 Yonsei-ro, Seoul, South Korea.
Background: Chemotherapy-related cardiotoxicity is a significant concern because it is a major cause of morbidity. This study aimed to provide in-depth information on the symptoms of chemotherapy-related cardiotoxicity (CRCT) by exploring literature that concurrently reports the types and symptoms of CRCT in patients with breast cancer.
Methods: A scoping review was performed according to an a priori protocol using the Joanna Briggs Institute's guidelines.
Artificial intelligence-enhanced risk stratification of cancer therapeutics-related cardiac dysfunction using electrocardiographic images.
medRxiv
March 2024
Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Article Synopsis
- This study explores an AI-enhanced electrocardiogram (AI-ECG) as a tool for risk stratification in patients at risk of cancer therapeutics-related cardiac dysfunction (CTRCD) rather than relying solely on specialized imaging techniques.
- Patients with breast cancer or non-Hodgkin lymphoma who received certain chemotherapy agents were analyzed, revealing that higher AI-ECG predictions of left ventricular systolic dysfunction (LVSD) correlated with worse heart function metrics and increased risk of future cardiac issues.
- The findings suggest that using AI on ECGs can effectively identify patients at greater risk for CTRCD associated with specific cancer treatments, potentially allowing for better management of these patients' heart health.
Long-Term Complete Response with Single-Agent Capecitabine in Her-2-neu-Positive Metastatic Breast Cancer-A Rare Case Report.
Indian J Surg Oncol
March 2024
Department of Surgical Oncology, SMS Medical College and Hospital, Jaipur, Rajasthan India.
The standard treatment approach for metastatic breast cancer with HR- and Her-2-neu + disease is trastuzumab with systemic therapy. But in patients having severe cardiac dysfunction, trastuzumab is avoided. Various combination regimens are available in that setting, but no study has shown better efficacy of capecitabine monotherapy in this setting.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!